Welcome to MBCN Buzz!
MBCN Buzz is a free newsletter produced by the Metastatic Breast Cancer Network (MBCN). To sign up for the electronic version, see http://www.mbcn.org/contact-us/
Got a tip? Please email me at email@example.com.
Thanks for reading!
Katherine O’Brien, editor, MBCN Buzz
General Treatment Info
Stay Tuned for More MBC News
If you want to track MBC treatment developments, watch for news from The American Society of Clinical Oncology meeting (ASCO) which takes place in June 1-5, 2018 in Chicago as well as the San Antonio Breast Cancer Symposium (SABCS) to be held December 4-8, 2018. Living Beyond Breast Cancer (LBBC.org) and SHARE Cancer Support (sharecancersupport.org) offer post-event free webinars that spotlight key MBC news. Watch the 2017 SABCS highlights here: https://www.sharecancersupport.org/report-back-from-sabcs-on-metastatic-breast-cancer/
Overview of MBC Treatments
The NCCN Quick Guide is a one-page summary of key points from the complete NCCN Guidelines for Stage IV Breast Cancer. These guidelines explain which tests and
treatments are recommended by experts in cancer. See: https://www.nccn.org/patients/guidelines/quick_guides/breast/stage_iv/files/assets/basic-html/page-1.html
Search Engine for MBC Trials
Are you looking for a metastatic breast cancer clinical trial? A new search engine, a project made possible by the Metastatic Breast Cancer Alliance, makes it easy to quickly identify trials appropriate to your situation. See https://www.breastcancertrials.org/BCTIncludes/AvonPfizer/BCTDemo.html or email MetastaticTrialSearch@gmail.com.
Brain Mets Basics
This website offers those with metastatic breast cancer and their families a place to learn about brain metastases from a patient perspective: www.brainmetsbc.org
Lobular Breast Cancer: The Latest Developments
There are significant differences in metastatic patterns between invasive ductal carcinoma (IDC) and invasive lobular cancer (ILC), including increased spread of ILC to gastrointestinal, peritoneal and ovarian tissues. If you have invasive lobular cancer (ILC), the newly formed Lobular Breast Cancer Alliance (LBCA) can help you understand the disease and stay current with the latest thinking. LBCA is a volunteer-based national network of patient-advocates working with breast cancer researchers and clinicians. See http://www.lobularbreastcancer.org/
Subtype Specific Info
The Big Three: Sorting Out the CDK 4/6 Inhibitors
CDK 4/6 inhibitors are revolutionizing treatment options for hormone-receptor-positive MBC. Palbociclib (Ibrance) has since been joined by Ribociclib (Kisqali) and a third option, Abemaciclib (Verzenio) has just been approved or the frontline treatment of postmenopausal women. Lilly also is actively evaluating Abemaciclib in lung cancer, pancreatic cancer, and patients with brain metastases.
For a CDK4/6 overview, see http://ecancer.org/video/6572/sabcs-2017–the-latest-in-cdk-inhibition-in-breast-cancer.php
Triple positive breast cancer: A distinct subtype?
Are you triple positive? This 2015 article reviews the existing literature on biologic and clinical data concerning the HER-2/ER/PgR positive tumors. It’s an attempt to better define the HER-2 subtypes and to optimize the use of HER-2 targeted agents, chemotherapy and endocrine treatments in the various subsets.
Two HER2 Targeted Therapies Plus AI Offers Potential ‘Alternative’ to Chemo
The ALTERNATIVE study suggests that in patients with HER2+/ HR+ metastatic breast cancer, combining dual HER2-targeted therapies with hormone therapy may be as effective as regimens that include chemo. Lapatinib (Tykerb) and trastuzumab (Herceptin)–combined with an AI significantly improved progression-free survival among patients vs. the single HER2-targeted therapy with an AI. See: http://news.feinberg.northwestern.edu/2018/01/drug-regimen-boosts-outcomes-for-some-breast-cancer-patients/
Blackwell Sheds Light on Recent Advances in HER2+ Breast Cancer
Duke Cancer Institute’s Kimberly Blackwell reviews HER2-positive breast cancer news, including the HER2CLIMB trial. It’s a dual targeted approach of tucatinib and trastuzumab with capecitabine in patients with unresectable locally advanced or metastatic HER2-positive disease with or without brain mets. See: http://www.onclive.com/web-exclusives/blackwell-sheds-light-on-recent-advances-in-her2-breast-cancer
Will Liquid Biopsy Help Predict Outcomes in Metastatic TNBC?
Researchers say this study suggests that minimally invasive liquid biopsies could be used as a new predictive marker for metastatic triple-negative breast cancer (TNBC). See https://cancer.osu.edu/news-and-media/news/liquid-biopsy-can-help-predict-outcomes-in-metastatic-triple-negative-breast-cancer
TNBC Drug Moving to Phase III Trial
Sacituzumab govitecan is being studied as a third-line treatment or beyond for metastatic TNBC. The single-arm phase II study included 110 patients with relapsed or refractory triple-negative breast cancer. The response rate was 30%, median progression-free survival was 5.5 months, and median overall survival was 12.7 months. See: http://www.ascopost.com/issues/january-25-2018/novel-antibody-drug-conjugate-active-in-refractory-triple-negative-breast-cancer/
Mark Your Calendar
Cancer & Careers: The free annual Midwest Conference on Work & Cancer will be held Friday, March 23, 2018, in Chicago at Northwestern. See: https://www.cancerandcareers.org/en/community/events/midwest-conference
Meet More Metsers: Join your fellow MBC patients and supporters in Philadelphia April 20-22 2018 at Living Beyond Breast Cancer’s (LBBC’s) Conference on Metastatic Breast Cancer. You can connect with others and learn about the latest medical research. See: http://www.lbbc.org/programs-events/2018-conference-metastatic-breast-cancer-0
Facebook groups for people living with MBC include the Metastatic Stage IV Breast Cancer Support group. These closed groups are a great way to give and get support—without leaving home! See https://www.facebook.com/MBCsupport/
Camp Kesem is a free sleep-away summer camp for kids whose parents have cancer. Slots fills up quickly! See http://campkesem.org
If you enjoyed Dr. Paul Kalanith’s “When Breath Becomes Air,” take a look at Nina Riggs’ “The Bright Hour.” The late Riggs, a young mom with MBC, offers a memoir that is both heartbreaking and hilarious. See: https://www.amazon.com/Bright-Hour-Memoir-Living-Dying/dp/1501169351
Do you find that people just don’t get it? This article may help—“10 Things Your Friend With Metastatic Breast Cancer Wants You to Know.” See: https://www.healthcentral.com/article/the-10-things-your-friend-with-metastatic-breast-cancer-wants-you-to-know?ap=2007